SELLAS Life Sciences Group, Inc.
NASDAQ:SLS · NASDAQ Capital Market
+$0.31 today
Vol 14.69M · Avg 7.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.9%
avg -314.2%
ROIC
-39.3%
avg -125.9%
ROA
-34.3%
avg -142.7%
Analysis
ROA is currently the strongest return metric at -34.3% versus its period average of -142.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Angelos Stergiou | Founder, President, Chief Executive Officer & Director | $1.07M | — | 50 | $686,966.00 | 0.48% |
Dragan Cicic | Senior Vice President & Chief Development Officer | $662,734.00 | — | 63 | $557,805.00 | 0.39% |
John Thomas Burns | Senior Vice President & Chief Financial Officer | $630,592.00 | — | 41 | $554,327.00 | 0.39% |
Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | — | — | — | — | — |
Stacy Yeung | VP, General Counsel & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$100,806.00
Sells
0
$0.00
Net Sentiment
+$100,806.00
Net buying
Most Active
Kalin Katherine Bach
1 transactions
Analysis
Insiders reported 1 buys worth $100,806.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $100,806.00. Kalin Katherine Bach was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$332.97M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$330.88M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$260.10M
OmniAb, Inc.
NASDAQ:OABI
$252.47M
Codexis, Inc.
NASDAQ:CDXS
$220.43M
Protara Therapeutics, Inc.
NASDAQ:TARA
$155.32M
MediWound Ltd.
NASDAQ:MDWD
$153.22M
Invivyd, Inc.
NASDAQ:IVVD
$130.22M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$96.78M
Who manages SLS?
SELLAS Life Sciences Group, Inc. (SLS) lists 5 active executives. The top listed executive is Angelos Stergiou, Founder, President, Chief Executive Officer & Director.
Are SLS insiders buying or selling?
Recent insider activity shows net buying of $7.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.